Chemical Structure : WMJ-J-09
CAS No.:
2416914-29-7
WMJ-J-09
Catalog No.: PC-24736Not For Human Use, Lab Use Only.
WMJ-J-09 a potent, hydroxamate based HDAC inhibitor, exhibits potent inhibitory activity against class I HDACs, including HDAC1 (IC50=7.5 nM), HDAC2 (IC50=21.3 nM), HDAC3 (IC50=18.4 nM), and HDAC8 (IC50=90.9 nM), also strongly inhibitsHDAC6 (class IIb) with IC50 of 3.9 nM.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Purity & Documentation Purity:
>98% (HPLC)
Biological Activity
WMJ-J-09 a potent, hydroxamate based HDAC inhibitor, exhibits potent inhibitory activity against class I HDACs, including HDAC1 (IC50=7.5 nM), HDAC2 (IC50=21.3 nM), HDAC3 (IC50=18.4 nM), and HDAC8 (IC50=90.9 nM), also strongly inhibitsHDAC6 (class IIb) with IC50 of 3.9 nM.
WMJ-J-09 arrests the cell cycle and induced apoptosis in HCT116 cells.
WMJ-J-09 shows moderate inhibition toward HDAC4 (class IIa) with an IC50 of 8715.7 nM.
WMJ-J-09 significantly reduces the polymerized tubulin fraction through HDAC inhibition.
WMJ-J-09 caused HCT116 cell death may involve p21 elevation and survivin suppression.
WMJ-J-09 triggers LKB1-p38MAPK-p53 signaling pathway to increases p21 expression and survivin reduction, culminating in HCT116 cell death.
WMJ-J-09 induced survivin degradation.
WMJ-J-09 (20 mg/kg/day) inhibits growth of the HCT116 tumor xenograft, does not impact mouse body weight.
Physicochemical Properties
|
M.Wt
|
445.53
|
|
Formula
|
C22H27N3O5S
|
|
Appearance
|
Solid
|
|
CAS No.
|
|
|
Storage
|
- Solide Powder
-
-20°C 12 Months; 4°C 6 Months
|
- In Solvent
-
-80°C 6 Months; -20°C 6 Months
|
|
Shipping
|
|
|
Solubility
|
10 mM in DMSO
|
|
Chemical Name/SMILES
|
N1-hydroxy-N8-(1-(phenylsulfonyl)indolin-6-yl)octanediamide
|
References
1. Yen CS, et al. Front Pharmacol. 2018 Mar 1;9:167.
2. Huang YH, et al. Sci Rep. 2025 Jun 4;15(1):19590.
Contact Us
sales@probechem.com
